Annual sunscreen expenses fluctuated between $40 and $1400 based on product pricing and concurrent sun-protective behaviors.

Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 response rates.

The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Patients with chronic back pain reported heightened unpleasantness of auditory stimuli and mechanical pressure.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Higher SUA levels were associated with a lower risk for osteoporosis, with sex, race, diabetes status, and serum cholesterol levels identified as potential modifiers.

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.

Adults with overweight or obesity regained most weight lost during GLP-1 receptor agonist treatment at 1 year following cessation.

Orally administered sucrose reduced pain scores during and shortly after venipuncture among neonates compared with standard care.

Testosterone replacement therapy before total knee arthroplasty was linked to higher risks for systemic and periprosthetic complications.